| abstract |
This invention relates to the combination of a certain amount of a GPR119 agonist with a certain amount of a dipeptyl peptidase IV inhibitor (DPP-IV), so that this combination provides the effect of lowering blood glucose or increasing the level of blood GLP-1 in a subject in excess of the effect provided by this amount of a GPR119 agonist or by this amount of the DPP-IV inhibitor individually, and to the use of such a combination for the treatment or prophylaxis of diabetes and related conditions or conditions improved by an increase in blood GLP-1 level. The present invention also relates to the use of a G-protein bound receptor for screening for GLP-1 secretion stimulants. |